Solana Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSDT research report →
Price Chart
About the company
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies.
- CEO
- Dane Carl Andreeff
- IPO
- 2014
- Employees
- 21
- HQ
- Newtown, PA, US
Get TickerSpark's AI analysis on HSDT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $108.60M
- P/E
- -0.06
- PEG
- 0.00
- P/S
- 9.00
- P/B
- 0.88
- EV/EBITDA
- -0.78
- Div Yield
- 0.00%
- Gross Margin
- 95.53%
- Op Margin
- -200.47%
- Net Margin
- -1302.78%
- ROE
- -122.85%
- ROIC
- -13.92%
Latest fiscal year · YoY change
- Revenue
- $6.02M+1057.1%
- Gross Profit
- $5.52M+8998.4%
- Op Income
- $-21,121,000
- Net Income
- $-40,890,000-248.2%
- EPS
- $-1.85+57.3%
- OCF Growth
- -49.6%
- FCF Growth
- -454.9%
- 52W High
- $25.50
- 52W Low
- $1.19
- 50D MA
- $1.68
- 200D MA
- $2.46
- Beta
- 1.01
- RSI (14)
- 60
- Avg Volume
- 265.17K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Solana Company reported sharply higher staking-driven revenue in Q2 2026, while building out its validator, advisory, and treasury flywheel and leaning on buybacks while the stock traded below NAV.· August 14, 2026
- Q2 revenue was $2.5 million, up from $43,000 in Q2 2025, driven by $2.5 million of staking revenue.
- Net loss was $30.3 million, or $0.38 per share, versus a $9.8 million loss a year ago, largely reflecting noncash digital asset fair-value swings and higher operating costs.
- The company said its average net staking yield was 6.14% APY versus a 5.68% network average, and it held about 2.3 million SOL worth about $170.6 million at quarter-end.
- Management highlighted a live validator cluster in Tokyo, a first third-party stake commitment of around 0.5 million SOL, and a new Hong Kong trust company acquisition.
- Capital allocation remained focused on accretion: the company repurchased $2.3 million of stock in Q2 and said it will keep buying back shares while the stock trades below NAV.
Second-quarter 2026 revenue was $2.5 million, consisting of $2.5 million of staking revenue and $14,000 of other revenue, versus $43,000 in Q2 2025. Gross profit was $2.4 million with a gross margin of approximately 97%, on $0.1 million of cost of revenue. General and administrative expenses were $11.1 million, compared with $3.3 million a year ago. The company recorded a net loss of $30.3 million, or $0.38 per basic and diluted share, versus a $9.8 million net loss in Q2 2025. As of June 30, 2026, it had $176.1 million of total assets, $3.6 million of cash and cash equivalents, and $170.6 million of SOL fair value holdings; liabilities were $6.4 million. For the first six months, revenue was $6.1 million and net loss was $130.1 million, or $1.66 per share. Forward, management expects Q3 to include first validator-related rewards, validator revenue from the first third-party stake, and continued conversion of the advisory pipeline into revenue; G&A is expected to decline and normalize back toward Q1 levels as PoNS costs roll off.
Joseph Chee framed the quarter as progress on a digital-asset treasury plus infrastructure strategy, saying the company is building a “flywheel” across advisory, validator infrastructure, and treasury. He emphasized that the Tokyo validator cluster is live, the first institutional third-party stake has been secured, and the legacy medical-device business has been exited. His tone was constructive and expansionary, with repeated references to Asia-Pacific institutional adoption and the company’s role as a named, regulated counterparty.
Madelene Gani walked through the financial impact of staking-led revenue growth and the expense profile tied to the transition. She noted G&A of $11.1 million in Q2, including about $6.8 million of nonrecurring severance tied to the PoNS divestiture, and said G&A should decline and normalize as the PoNS cost base rolls off. She also highlighted noncash digital asset fair-value movements, including a $2.4 million unrealized gain, a $25.4 million realized loss from strategic sales, and a $0.3 million unrealized fund loss, and pointed to balance-sheet strength with $3.6 million of cash, $176.1 million of assets, and $6.4 million of liabilities. She said the company repurchased 1.3 million shares under its program and that treasury stock stood at $5.9 million, representing 2.9 million shares at cost.
Analysts focused on how Pacific Backbone will monetize and whether it can become a revenue contributor quickly. Joseph Chee said the Tokyo validator is not merely a cost center and that third-party SOL was secured almost immediately after launch, adding that he expects it to be profitable this year, though he declined to give specific revenue guidance. Questions also centered on capital allocation and possible consolidation of other SOL digital-asset treasuries; Cosmo Jiang said the company will keep maximizing SOL per share through buybacks when shares trade below NAV, while also staying open to strategic capital raises or other transactions that create accretion.
Management said core operating pieces are now in place: a live validator cluster, a first institutional stake commitment, an advisory pipeline, and a profitable Hong Kong trust company acquisition. They also reported staking yield above the network average and continued buybacks below NAV, which they described as accretive to SOL per share. The company’s tone was confident that institutional demand in Asia-Pacific is growing and that revenue from validator and advisory lines should start to show up in coming quarters.
The quarter still showed a large net loss and heavy G&A, with much of the expense burden tied to restructuring and the PoNS exit. Management did not provide specific revenue guidance for the validator business beyond expecting first validator-related rewards in Q3 and saying more detail would come later. The stock traded at a discount to NAV, which management framed as an opportunity for buybacks, but that also underscores market skepticism and leaves the company dependent on continued execution to justify its strategy.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.1%
- Shares Outstanding
- 58.39M
- Float Shares
- 40.33M
of shares held by institutions
47 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 488.21K | ▲ 488.21K |
Held by 5 ETFs
Biggest fund positions in HSDT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | Chee Choon Wee | other | 923,000 |
| May 11, 26 | Summer Wisdom Holdings Ltd | other | 1,453,277 |
| Sep 18, 25 | Summer Wisdom Holdings Ltd | other | 0 |
| Sep 18, 25 | Summer Wisdom Holdings Ltd | other | 6,830,402 |
| Sep 18, 25 | Summer Wisdom Holdings Ltd | other | 2,218,236 |
| Jun 2, 26 | Jiang Cosmo Yi | other | 1,005,040 |
| Jun 2, 26 | Jiang Cosmo Yi | other | 1,005,040 |
| Jun 2, 26 | Jiang Cosmo Yi | other | 610 |
| Sep 18, 25 | Jiang Cosmo Yi | other | 1,005,040 |
| May 21, 26 | Mello Sergio | other | 18,564 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HSDT coverage
Recent articles, reports, and earnings notes.
No research on HSDT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HSDT report →Solana Company (HSDT) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 14
Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Aug 14
Solana Q2 Earnings Call Highlights
marketbeat.com · Aug 14
Solana Company Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 14
Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
globenewswire.com · Aug 12
Solana Company Partners with Alatau City to Advance Digital Asset Infrastructure and Blockchain Adoption in Central Asia
globenewswire.com · Jun 30
Solana Company Board Unanimously Rejects Unsolicited Forward Industries Proposal
globenewswire.com · Jun 16
UPDATED: Forward Industries Announces Letter of Intent to Acquire Solana Company (HSDT)
globenewswire.com · Jun 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.